New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
18:29 EDTTRAK, GERN, CALL, HEAR, MTZ, MM, NUAN, GALE, SMG, CEMP, ICPT, HALO, GSAT, DSTI, SFMOn The Fly: After Hours Movers
UP AFTER EARNINGS: DealerTrack (TRAK), up 11.3%... DTS Inc. (DSTI), up 12.8%... Globalstar (GSAT), up 1.6%... Halozyme Therapeutics (HALO), up 2.4%. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 57.7% after announcing that 46% of OCA group met FLINT endpoint as well as reporting second quarter results... Cempra (CEMP), up 5.8% following Intercept Pharmaceuticals' FLINT announcement... Scotts Miracle-Gro (SMG), up 3.6% after board approves a $500M share repurchase authorization and announces a $2.00 per share special dividend. DOWN AFTER EARNINGS: Galena Biopharma (GALE), down 13.4%... Nuance Communications (NUAN), down 9.7%... Millennial Media (MM), down 7.1%... MasTec (MTZ), down 3.6%... Turtle Beach (HEAR), down 3.5%... magicJack (CALL), down 5.8%... Geron (GERN), down 2.4%. ALSO LOWER: Sprouts Farmers Market (SFM), down 3.7% after filing to sell 15M shares of common stock for holders.
News For TRAK;DSTI;GSAT;HALO;ICPT;CEMP;SMG;GALE;NUAN;MM;MTZ;HEAR;CALL;GERN;SFM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 17, 2014
09:06 EDTCEMPCempra enters $50M equity sales agreement with Cowen
Subscribe for More Information
October 16, 2014
15:22 EDTGERNGeron volatility increases to 134
Geron overall option implied volatility of 134 is above its 26-week average of 106 according to Track Data, suggesting large price movement.
October 15, 2014
13:14 EDTNUANNuance upgraded to Buy from Hold at Standpoint Research
Subscribe for More Information
09:21 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
07:24 EDTICPTIntercept management to meet with Deutsche Bank
Subscribe for More Information
October 14, 2014
07:17 EDTGALEGalena receives notice of allowance of improvement patent for NeuVax in Japan
Galena Biopharma announced the notice of allowance from the Japanese Patent Office for NeuVax covering the use of NeuVax alone or in combination with other agents to prevent recurrence of any HER2/neu expressing breast cancer tumor having an immunohistochemistry level of 1+ or 2+, or a fluorescence in situ hybridization rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent will expire in 2027, not including any patent term extensions.
October 13, 2014
14:25 EDTGSATGlobalstar responds to Kerrisdale Capital's FCC filing
Subscribe for More Information
06:42 EDTSFMSprouts Farmers Markets upgraded to Buy from Neutral at SunTrust
Subscribe for More Information
October 9, 2014
16:22 EDTGSATGlobalstar to make new investor presentation available on October 9 at 4:30pm ET
Globalstar announced that it will make available a new investor presentation that outlines the company's value proposition, long-term prospects and the industry landscape, as well as directly refutes Kerrisdale Capital's flawed assertions regarding the company. The presentation will be made available on the company's website at the commencement of the Globalstar conference call today, October 9 at 4:30 p.m. EDT. "We remain as confident as ever in the strength of Globalstar's value proposition and competitive advantage, now and in the future," said Jay Monroe, Chairman and CEO of Globalstar. "This is a critical juncture in the communications industry, and Globalstar is well positioned with unique capabilities and assets to capture the opportunities of the constantly evolving landscape. We continue to benefit from a completed second-generation constellation, a strengthened balance sheet and liquidity position, substantial operating growth and achievement of significant milestones on the proceeding for our Terrestrial Low Power Service with the Federal Communications Commission." Monroe continued, "Today's presentation reiterates what we at Globalstar have always known that the facts are indisputably on our side. Kerrisdale's analysis lacks credibility and any real understanding of the fundamentals and current state of our industry. What is clear is that Kerrisdale stands alone in its views, which staunchly contradict the prevailing perspectives of regulators and major industry players. We stand united in our commitment to supporting our assets, strategy and ability to capitalize on significant future growth opportunities."
09:03 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
07:59 EDTGSATGlobalstar to host conference call
Conference call to address the matters raised during the October 6th Kerrisdale Capital presentation will be held on October 9 at 4:30 pm. Webcast Link
October 8, 2014
18:31 EDTNUANOn The Fly: After Hours Movers
UP AFTER EARNINGS: Ruby Tuesday (RT), up 19.6%... Exar (EXAR), up 13.7% after reporting second quarter revenue guidance... Alcoa (AA), up 2.2%. ALSO HIGHER: Nuance (NUAN), up 2.5% following rumors that Carl Icahn will recommend that Apple (AAPL) buy the company... GrubHub (GRUB), up just under 1% after being initiated with a Buy at CRT Capital. DOWN AFTER EARNINGS: Kofax (KFX), down 20.1% after reporting first quarter revenue and fiscal 2015 revenue guidance below analyst estimates... ARC Group (ARCW), down 17%... E2open (EOPN), down 8.9%. ALSO LOWER: Gap (GPS), down 7.6% following September same store sales data and CEO transition... AMD (AMD), down 7% after announcing CEO transition.
16:26 EDTNUANOn The Fly: Closing Wrap
Subscribe for More Information
15:12 EDTNUANNuance October calls active amid speculation Icahn speculation
Subscribe for More Information
15:05 EDTNUANRumor: Nuance moves off lows amid Icahn speculation
Subscribe for More Information
12:42 EDTICPTIntercept weakness a buying opportunity, says Wedbush
Subscribe for More Information
12:11 EDTICPTIntercept management to meet with Oppenheimer
Subscribe for More Information
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
07:09 EDTGALEGalena reports Notice of Allowance of U.S. patent application for NeuVax
Subscribe for More Information
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use